IUCRO-0498; Role of Osteocytes in Myeloma Bone Disease

Recruiting
18 years - 95 years
All
Phase N/A
1 Location

Brief description of study

The purpose of this study is to learn if substances that may cause bone destruction are increased in blood or bone marrow.

Detailed description of study

The investigators hope to determine serum FGF23 and heparanase, Dkk1 and plasma klotho levels in patients with newly diagnosed and relapsed myeloma compared to healthy controls with this exploratory study.

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Healthy,Multiple Myeloma
  • Age: 18 years - 95 years
  • Gender: All

Inclusion Criteria
English-speaking
Have no known liver or kidney disorders
Have no prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin
Exclusion Criteria
Pregnant
Allergic to xylocaine
Acute illness in the past seven days
History of bleeding disorders
Prisoners

Updated on 04 Aug 2024. Study ID: 1407589587

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team